The sale of Stockport based Surgichem, a leading provider of medication adherence packaging solutions to UK care home and domiciliary care markets, has completed having been acquired by US based Omnicell.
Omnicell, a leading provider of medication and supply management solutions to healthcare systems, today announced that it has completed the acquisition of the wholly-owned subsidiary of Bupa Care Homes (CFG) plc.
Following the recent clearance by the Competition Commission after it identified concerns about possible increased prices and/or a worsening of services to pharmacies for ‘adherence packaging’ products, Surgichem will be integrated with Omnicell’s existing UK business, MTS Medication Technologies Limited in the coming months. MTS Medication Technologies Limited is the world’s leading supplier of medication adherence packaging solutions.
Surgichem supplies its monitored dosage systems to a network of over 3,200 independent pharmacies and UK pharmacy chains.
Randall Lipps, chairman, president and CEO of Omnicell said:
“As is the case globally, UK healthcare professionals and caregivers are seeking to improve patient outcomes, reduce medication errors and lower costs by effectively managing compliance to prescribed medication regimes. This acquisition is a clear opportunity to bring together the experience of two technology leaders with the mission to extend patient health and satisfaction through convenient, effective medication adherence solutions.
“Omnicell is committed to improving medication adherence in the UK. We expect that combining the leading multi- and single-dose packaging technologies of MTS Medication Technologies with the very complementary Surgichem offering will help to solve the issue by speeding the development of new products and services for the UK adherence market, benefiting our pharmacy customers and their patients.
“Omnicell is passionate about our mission to make taking medication as easy and safe as possible for everyone.”